For complex targets such as protein interaction, the binding pocket is relatively flat, and the compound is difficult to bind, and HTS is almost ineffective in this field, while FBDD can first identify small fragments with weak binding, further optimize the structure, and obtain potential pharmaceutical compounds.
Several small molecule drugs have been discovered in this way, with more than 30 entering the clinical stage, as well as two marketed drugs: Vemurafenib and Venetoclax.
Given the successful application of FBDD method, it will be more favored by drug development experts in the field of drug development.

A good fragment library is a prerequisite for the success of FBDD methods. For fragment libraries, it is generally necessary to consider the Ro3 principle (mw<300, HBA<3, HBD<3, Rotable bond<3, cLogP<3), 3D structural diversity, solubility, etc. In addition, some researchers are interested in libraries of fragments containing specific groups, such as fluorinated fragments, bromine fragments, etc.
Combined with the experimental characteristics, selecting the appropriate fragment library can narrow the screening scope, design drugs more rationally, and reduce the difficulty for subsequent drug development. The Drug Screen has collected a library of more than 50 fragments of compounds to provide researchers with more options.